Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Cash from Operations (2022 - 2025)

Historic Cash from Operations for Atara Biotherapeutics (ATRA) over the last 4 years, with Q3 2025 value amounting to -$9.8 million.

  • Atara Biotherapeutics' Cash from Operations fell 14534.97% to -$9.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$69.7 million, marking a year-over-year increase of 2634.7%. This contributed to the annual value of -$68.7 million for FY2024, which is 6439.11% up from last year.
  • According to the latest figures from Q3 2025, Atara Biotherapeutics' Cash from Operations is -$9.8 million, which was down 14534.97% from -$7.3 million recorded in Q2 2025.
  • Over the past 5 years, Atara Biotherapeutics' Cash from Operations peaked at -$4.0 million during Q3 2024, and registered a low of -$84.5 million during Q1 2022.
  • Its 4-year average for Cash from Operations is -$38.5 million, with a median of -$38.4 million in 2023.
  • Per our database at Business Quant, Atara Biotherapeutics' Cash from Operations soared by 9223.11% in 2024 and then crashed by 14534.97% in 2025.
  • Over the past 4 years, Atara Biotherapeutics' Cash from Operations (Quarter) stood at -$56.9 million in 2022, then increased by 11.38% to -$50.4 million in 2023, then soared by 51.45% to -$24.5 million in 2024, then skyrocketed by 60.01% to -$9.8 million in 2025.
  • Its Cash from Operations was -$9.8 million in Q3 2025, compared to -$7.3 million in Q2 2025 and -$28.1 million in Q1 2025.